Ethical issues of using artificial intelligence in drug development
https://doi.org/10.37489/2588-0519-2025-3-111-117
EDN: QFCFBK
Abstract
Artificial intelligence (AI) is being actively integrated into the drug development process, significantly accelerating it and reducing the costs of creating new therapeutic agents. This article examines key areas of AI application in the pharmaceutical industry, including molecular structure prediction, virtual compound screening, optimization of clinical trials, and personalized medicine. Special attention is paid to the ethical issues arising from the use of AI, such as algorithm transparency, accountability for errors, data privacy, technology accessibility, and regulatory challenges. The World Health Organization (WHO) guidelines for managing large multi-modal models in healthcare are analyzed. The article emphasizes the need to strike a balance between innovation and ethical responsibility, as well as to develop a regulatory framework for the safe and effective use of AI in medicine.
About the Authors
A. L. Khokhlov
Yaroslavl State Medical University
Russian Federation
Competing Interests:
Russian Federation
Alexander L. Khokhlov — Dr. Sci (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Pharmacology and Clinical Pharmacology, Rector
Yaroslavl
Competing Interests:
The authors declare no conflict of interest
D. Yu. Belousov
Center for Pharmacoeconomic Research LLC
Russian Federation
Competing Interests:
Russian Federation
Dmitry Yu. Belousov — General Director
Moscow
Competing Interests:
The authors declare no conflict of interest
References
1. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010.
2. Dunn Andrew. Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution. Endpoints News. [Internet] Режим доступа: https:// endpts.com/inside-nvidias-plan-to-dominate-biotechs-ai-revolution/
3. Svechkareva IR, Gusev AV, Kolbin AS. Artificial intelligence in preclinical studies and clinical trials. Klini cheskaya farmakologiya i terapiya = Clin Pharmacol Ther. 2025;34(1):14-19 (In Russ.). DOI 10.32756/0869-5490-2025-1-14-19.
4. Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. Mol Divers. 2022 Jun;26(3):1893-1913. doi: 10.1007/s11030-021-10326-z.
5. Dunn Andrew. Q&A: Insitro CEO Daphne Koller on ‘potentially destructive’ AI hype, Nvidia's chips, and biotech's data problem. Endpoints News. [Internet] Режим доступа: https://endpts.com/insitro-ceo-daphne-koller-on-potentially-destructive-ai-hype-nvidia-chips-and-biotechs-data-problem/
6. Zhu H. Big Data and Artificial Intelligence Modeling for Drug Discovery. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:573-589. doi: 10.1146/annurev-pharmtox-010919-023324.
7. Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, Courville A, Bengio Y. Generative Adversarial Networks. arXiv. 2014.1406.2661. https://doi.org/10.48550/arXiv.1406.2661.
8. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32(1-2):51-63. doi: 10.1016/0021-9681(79)90012-2.
9. Ethics and governance of artificial intelligence for health. Guidance on large multi-modal models. World Health Organization 2024. Available at: https://iris.who.int/bitstream/handle/10665/375579/9789240084759-eng.pdf.
10. Malichenko VS, Gadzhieva AO, Platonova NI, Solovieva-Oposhnyanskaya AYu. Legal particularities of AI technology usage in real-world data formation. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(4):657-70 (In Russ.).
Review
For citations:
Khokhlov A.L., Belousov D.Yu. Ethical issues of using artificial intelligence in drug development. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2025;(3):111-117. (In Russ.) https://doi.org/10.37489/2588-0519-2025-3-111-117. EDN: QFCFBK
Views:
30
Email this article 